Previous 10 | Next 10 |
2024-05-29 09:29:04 ET More on Mind Medicine MindMed releases promising phase 2 data on LSD-related anxiety therapy MindMed: Breakthrough Status From The FDA For LSD Therapy Psychedelics Closer To Commercialization; Compass Far And Away The Leader Mind Medici...
2024-05-28 17:04:47 ET Gainers: Blue World Acquisition ( BWAQ ) +57% . Insmed ( INSM ) +33% . Vivid Seats ( SEAT ) +8% . Ocular Therapeutix ( OCUL ) +7% . Mind Medicine ( MNMD ) +7% . Losers: Inhib...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participa...
2024-05-23 12:15:00 ET Summary Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. Analyst Alex Carchidi disc...
Legislators in Vermont have approved a measure that would establish a task force for psychedelic therapy. The group’s primary task would be to recommend how and whether the state should regulate legal access to psychedelic drugs such as MDMA and psilocybin. The legislation is now headed ...
2024-05-10 11:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap ...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participa...
- GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life- -People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD- -Comprehensive Analyses of GAD Disease Burden in the US Conducted b...
2024-05-08 21:07:02 ET Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Conference Call May 08, 2024 04:30 PM ET Company Participants Robert Barrow - Chief Executive Officer Daniel Karlin - Chief Medical Officer Francois Lilienthal - Chief Commercial Officer ...
2024-05-08 16:42:28 ET More on Mind Medicine MindMed: Breakthrough Status From The FDA For LSD Therapy Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data Mind Medicine (MindMed) Inc. (MNMD) Q4 2023 Earnings Call Transcript MindM...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...